Hyloris Pharmaceuticals Valuation
Is HYL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HYL?
Other financial metrics that can be useful for relative valuation.
| What is HYL's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €350.00m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 104x |
| Enterprise Value/EBITDA | -29.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does HYL's PB Ratio compare to its peers?
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3x | ||
MITRA Mithra Pharmaceuticals | 3.9x | 58.0% | €131.3m |
TUB Financière de Tubize | 1.9x | n/a | €3.3b |
UCB UCB | 1.8x | 23.7% | €15.9b |
MRNS Marinus Pharmaceuticals | 4.8x | 31.5% | US$387.2m |
HYL Hyloris Pharmaceuticals | 6.4x | 101.0% | €350.0m |
Price-To-Book vs Peers: HYL is expensive based on its Price-To-Book Ratio (6.4x) compared to the peer average (3x).
Price to Earnings Ratio vs Industry
How does HYL's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Book vs Industry: HYL is expensive based on its Price-To-Book Ratio (6.4x) compared to the European Pharmaceuticals industry average (2x)
Price to Book Ratio vs Fair Ratio
What is HYL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.4x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate HYL's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of HYL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HYL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HYL's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.